You can buy or sell RDY and other stocks, options, ETFs, and crypto commission-free!
Dr. Reddy's Laboratories Ltd. engages in the manufacture and marketing of pharmaceutical products. Read More It operates through the following segments: Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), Proprietary Products, and Others. The Global Generics segment is consist of manufacturing and marketing of prescription and over-the-counter finished pharmaceutical products ready for consumption by the patient, marketed under a brand name or as generic finished dosages with therapeutic equivalence to branded formulations. The PSAI segment is comprised of manufacturing and marketing of active pharmaceutical ingredients and intermediates, also known as API or bulk drugs, which are principal ingredients for finished pharmaceutical products. The Proprietary Products segment focuses on research, development, and manufacture of differentiated formulations and new chemical entities. The Others segment includes the operations of the wholly-owned subsidiary of the company, Aurigene Discovery Technologies Limited, a discovery stage biotechnology company developing novel and best-in-class therapies in the fields of oncology and inflammation and which works with pharmaceutical and biotechnology companies in early-stage collaborations, brining drug candidates for pre-clinical development. The company was founded by Kallam Anji Reddy on February 24, 1984 and is headquartered in Hyderabad, India.
52 Week High
52 Week Low
Advertising and Marketing
Yahoo FinanceMay 20
Dr. Reddy's Q4 Earnings Up Y/Y, Revenues Top Estimates
Dr. Reddy's Laboratories Ltd. RDY reported fourth-quarter fiscal 2019 earnings of 38 cents per share, up from 26 cents in the year-ago quarter, per American Depositary Share (ADS). Moreover, revenues increased 14% year over year to $581 million. Revenues also surpassed the Zacks Consensus Estimate of $565 million. Year to date, shares of the company have increased 4.5% against the industry’s decline of 2.9%. Scroll to continue with content Ad Quarter in Detail Dr. Reddy’s reported revenues under three ...
Seeking AlphaMay 17
Dr. Reddy's Laboratories Ltd CEO Gunupati Prasad on Q4 2019 Results - Earnings Call Transcript
Dr. Reddy's Laboratories Ltd (NYSE:RDY) Q4 2019 Earnings Conference Call May 17, 2019 8:30 AM ET Company Participants Amit Agarwal - Director, Finance, FP&A & IR Gunupati Prasad - CEO Saumen Chakraborty - CFO Erez Israeli - COO Anil Namboodiripad - SVP, Head, Proprietary Products & Head, Promius Pharma Conference Call Participants Prakash Agarwal - Axis Capital Limited Neha Manpuria - JPMorgan Chase & Co. Anubhav Aggarwal - Crédit Suisse Surya Patra - PhillipCapital Vishal Manchanda - Nirmal Ban...
Yahoo FinanceMay 17
Dr. Reddy’s Q4 & FY19 Financial Results
HYDERABAD, India--(BUSINESS WIRE)-- Dr. Reddy’s Laboratories Ltd. (BSE: 500124 | NSE: DRREDDY | NYSE: RDY) today announced its consolidated financial results for the fourth quarter and full year ended March 31, 2019 under International Financial Reporting Standards (IFRS). Q4 Performance Summary FY19 Performance Summary Rs.4,017 Cr Rs.15,385 Cr Revenue Revenue [Up: 14% YoY] [Up: 8% YoY] 52.4% 54.2% Gross Margin Gross Margin [Q4 FY18: 53.5%] [FY18: 53.7%] Rs.1,238 Cr Rs.4,889 Cr SGNA expenses SGNA expenses...
$0.38 per share